Daily non-political popular news in brief.

Hepatitis C treatment reduces the virus but serious liver problems may progress

Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon. However, the treatment did not slow or prevent the progression of serious liver disease. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis, and were reported at the annual meeting of the American Association for the Study of Liver Disease

Read more »

Keywords: hepatitis, treatment, virus, serious, liver, problems, progress, hepatiti, viru, seriou, problem

« Previous | Next »

Similar news on "Hepatitis C treatment reduces the virus but serious liver problems may progress":

1. Widely used hepatitis B drug spurs HIV drug resistance
   02-28-2007 · EurekAlert!
   A Johns Hopkins study has proven false established medical practice that an antiretroviral drug widely used to treat hepatitis B liver infections was safe to use on its own in patients co-infected with HIV. Their findings demonstrate that treatment with entecavir leads to cross-resistance to other antiviral drugs used to treat the AIDS virus.
   Similar news · Read more »
   
2. Attention: Extra-hepatic manifestation of hepatitis C virus infection
   01-16-2008 · EurekAlert!
   Hepatitis C virus is a major health problem worldwide, and more than 3 percent of the world's population is infected with HCV. Despite popular belief, HCV is not only a liver disease, but affects many organs, tissues, and systems.
   Similar news · Read more »
   
3. Can liver cirrhosis be partially cured?
   10-10-2007 · EurekAlert!
   A new therapeutic schedule of treatment was used with good results when dealing with patients suffering from liver cirrhosis following hepatitis C virus infection. Recent scientific evidence from Naples, Italy, is introduced.
   Similar news · Read more »
   
4. Liver fibrosis will be treated by a potential target
   10-16-2007 · EurekAlert!
   The hepatitis is either self recovery or its development into liver fibrosis or, further, liver cirrhosis. Since no ideal drug is available, liver fibrosis is currently considered to be a major worldwide health problem. A research conducted by by Dr. ZH Liu from Jilin University found that ARIP2 participates in the negative feedback regulation of signal transduction in the late stage by affecting the expression of ActRIIA, which further suggests that ARIP2 might be a potential target for treatment of liver fibrosis induced by activin.
   Similar news · Read more »
   
5. 24-week course of interferon-alpha therapy prolongs survival in patients hepatitis C virus
   11-02-2007 · EurekAlert!
   A group at Hiroshima University Hospital performed a matched historical controlled study on whether a 24-week course of interferon-alpha therapy, after curative treatment for primary hepatocellular carcinoma associated with hepatitis C virus, could influence tumor recurrence, patient survival, and liver function. Patients with sustained virological responses had reduced recurrence, prolonged survival and a preserved liver function. The group also determined that viral eradication was the most important factor in such patients.
   Similar news · Read more »
   
6. Racial differences seen in steatosis in patients with hepatitis C
   01-02-2007 · EurekAlert!
   Caucasian patients with chronic hepatitis C virus (HCV) are more likely to have hepatic steatosis, or fat in the liver, compared to African-American patients. However, steatosis is not associated with HCV treatment response.
   Similar news · Read more »
   
7. Possible hepatitis C vaccine
   09-05-2007 · EurekAlert!
   The hepatitis C virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed. It is the single biggest cause of people requiring a liver transplant in Britain. Now, in a collaborative effort with groups across Europe and the US, scientists from the University of Nottingham have found monoclonal antibodies which may be a significant step towards a vaccine.
   Similar news · Read more »
   
8. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
   12-28-2007 · EurekAlert!
   For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease. This problem is compounded by the fact that standard antiviral treatment for the disease can further reduce platelet numbers to dangerously low levels, effectively denying these patients the treatment they urgently need. Now, research published in the New England Journal of Medicine finds that a new drug, eltrombopag, appears to significantly boost platelet counts, opening the door to effective treatment.
   Similar news · Read more »
   
9. Shorter HCV treatment shows notable success
   01-02-2008 · EurekAlert!
   Two new randomized controlled trials show that treating Hepatitis C with peginterferon and ribavirin for shorter durations can yield success rates similar to those from longer treatment lengths, with cost-savings and lower risk of serious side effects.
   Similar news · Read more »
   
10. Quick-burning carbs may cause fatty liver
    09-20-2007 · EurekAlert!
    The obesity epidemic has spawned not just diabetes, but another serious public health problem: a surge in fatty liver disease, which can lead to cirrhosis and liver failure. Now, research suggests that limiting consumption of high-glycemic-index carbohydrates can prevent the condition in mice. A clinical trial is now testing this idea in overweight adolescents, as well as the possibility of reversing fatty liver disease through diet.
    Similar news · Read more »